Literature DB >> 17019404

Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval.

Eva M Fekete1, Koki Inoue, Yu Zhao, Jean E Rivier, Wylie W Vale, Attila Szücs, George F Koob, Eric P Zorrilla.   

Abstract

Brain corticotropin-releasing factor/urocortin (CRF/Ucn) systems are hypothesized to control feeding, with central administration of 'type 2' urocortins producing delayed anorexia. The present study sought to identify the receptor subtype, brain site, and behavioral mode of action through which Ucn 3 reduces nocturnal food intake in rats. Non-food-deprived male Wistar rats (n=176) were administered Ucn 3 into the lateral (LV) or fourth ventricle, or into the ventromedial or paraventricular nuclei of the hypothalamus (VMN, PVN) or the medial amygdala (MeA), regions in which Ucn 3 is expressed in proximity to CRF(2) receptors. LV Ucn 3 suppressed ingestion during the third-fourth post-injection hours. LV Ucn 3 anorexia was reversed by cotreatment with astressin(2)-B, a selective CRF(2) antagonist and not observed following equimole subcutaneous or fourth ventricle administration. Bilateral intra-VMN and intra-PVN infusion, more potently than LV infusion, reduced the quantity (57-73%) and duration of ingestion (32-68%) during the third-fourth post-infusion hours. LV, intra-PVN and intra-VMN infusion of Ucn 3 slowed the eating rate and reduced intake by prolonging the post-meal interval. Intra-VMN Ucn 3 reduced feeding bout size, and intra-PVN Ucn 3 reduced the regularity of eating from pellet to pellet. Ucn 3 effects were behaviorally specific, because minimal effective anorectic Ucn 3 doses did not alter drinking rate or promote a conditioned taste aversion, and site-specific, because intra-MeA Ucn 3 produced a nibbling pattern of more, but smaller meals without altering total intake. The results implicate the VMN and PVN of the hypothalamus as sites for Ucn 3-CRF(2) control of food intake.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17019404      PMCID: PMC2748839          DOI: 10.1038/sj.npp.1301214

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  82 in total

1.  Long-term effects on feeding and body weight after stimulation of forebrain or hindbrain CRH receptors with urocortin.

Authors:  H J Grill; S Markison; A Ginsberg; J M Kaplan
Journal:  Brain Res       Date:  2000-06-09       Impact factor: 3.252

2.  Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist.

Authors:  Glenn R Valdez; Eric P Zorrilla; Jean Rivier; Wylie W Vale; George F Koob
Journal:  Brain Res       Date:  2003-08-08       Impact factor: 3.252

3.  The physiology of motivation.

Authors:  E STELLAR
Journal:  Psychol Rev       Date:  1954-01       Impact factor: 8.934

4.  Corticotropin releasing factor receptor type II (CRF2) messenger ribonucleic acid levels in the hypothalamic ventromedial nucleus of the infant rat are reduced by maternal deprivation.

Authors:  M Eghbal-Ahmadi; C G Hatalski; S Avishai-Eliner; T Z Baram
Journal:  Endocrinology       Date:  1997-11       Impact factor: 4.736

5.  Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.

Authors:  Sam R J Hoare; Susan K Sullivan; Jun Fan; Khamkeo Khongsaly; Dimitri E Grigoriadis
Journal:  Peptides       Date:  2005-03       Impact factor: 3.750

6.  Topographic mapping of VMH --> arcuate nucleus microcircuits and their reorganization by fasting.

Authors:  Scott M Sternson; Gordon M G Shepherd; Jeffrey M Friedman
Journal:  Nat Neurosci       Date:  2005-09-18       Impact factor: 24.884

7.  Expression of corticotropin-releasing factor and its receptors in the brain of lean and obese Zucker rats.

Authors:  D Richard; R Rivest; N Naïmi; E Timofeeva; S Rivest
Journal:  Endocrinology       Date:  1996-11       Impact factor: 4.736

8.  Ventromedial hypothalamic syndrome: finickiness?

Authors:  R H Peters; L L Luttmers; M W Gunion; P J Wellman
Journal:  Physiol Behav       Date:  1978-03

9.  Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors.

Authors:  T M Reyes; K Lewis; M H Perrin; K S Kunitake; J Vaughan; C A Arias; J B Hogenesch; J Gulyas; J Rivier; W W Vale; P E Sawchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

10.  Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity.

Authors:  Olaf Jahn; Hossein Tezval; Lars van Werven; Klaus Eckart; Joachim Spiess
Journal:  Neuropharmacology       Date:  2004-08       Impact factor: 5.250

View more
  44 in total

1.  Perifornical Urocortin-3 mediates the link between stress-induced anxiety and energy homeostasis.

Authors:  Yael Kuperman; Orna Issler; Limor Regev; Ifat Musseri; Inbal Navon; Adi Neufeld-Cohen; Shosh Gil; Alon Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

2.  Type 2 corticotropin-releasing factor receptor in the ventromedial nucleus of hypothalamus is critical in regulating feeding and lipid metabolism in white adipose tissue.

Authors:  Hongxia Chao; Michael Digruccio; Peilin Chen; Chien Li
Journal:  Endocrinology       Date:  2011-11-08       Impact factor: 4.736

3.  Role of the corticotropin-releasing factor receptor type 2 in the control of food intake in mice: a meal pattern analysis.

Authors:  A Tabarin; Y Diz-Chaves; D Consoli; M Monsaingeon; T L Bale; M D Culler; R Datta; F Drago; W W Vale; G F Koob; E P Zorrilla; A Contarino
Journal:  Eur J Neurosci       Date:  2007-10       Impact factor: 3.386

4.  Distribution and axonal projections of neurons coexpressing thyrotropin-releasing hormone and urocortin 3 in the rat brain.

Authors:  Gábor Wittmann; Tamás Füzesi; Zsolt Liposits; Ronald M Lechan; Csaba Fekete
Journal:  J Comp Neurol       Date:  2009-12-20       Impact factor: 3.215

Review 5.  Corticotropin releasing factor: a key role in the neurobiology of addiction.

Authors:  Eric P Zorrilla; Marian L Logrip; George F Koob
Journal:  Front Neuroendocrinol       Date:  2014-01-20       Impact factor: 8.606

6.  Somatostatin and corticotrophin releasing hormone cell types are a major source of descending input from the forebrain to the parabrachial nucleus in mice.

Authors:  Ali Magableh; Robert Lundy
Journal:  Chem Senses       Date:  2014-08-02       Impact factor: 3.160

Review 7.  Remembering to eat: hippocampal regulation of meal onset.

Authors:  Marise B Parent; Jenna N Darling; Yoko O Henderson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-02-26       Impact factor: 3.619

8.  Injection of Urocortin 3 into the ventromedial hypothalamus modulates feeding, blood glucose levels, and hypothalamic POMC gene expression but not the HPA axis.

Authors:  Peilin Chen; Joan Vaughan; Cindy Donaldson; Wylie Vale; Chien Li
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-12-01       Impact factor: 4.310

9.  Quantitative trait locus for body weight identified on rat chromosome 4 in inbred alcohol-preferring and -nonpreferring rats: potential implications for neuropeptide Y and corticotrophin releasing hormone 2.

Authors:  John Paul Spence; Dongbing Lai; Anantha Shekhar; Lucinda G Carr; Tatiana Foroud; Tiebing Liang
Journal:  Alcohol       Date:  2013-02       Impact factor: 2.405

10.  Comparison of somatostatin and corticotrophin-releasing hormone immunoreactivity in forebrain neurons projecting to taste-responsive and non-responsive regions of the parabrachial nucleus in rat.

Authors:  Siva Panguluri; Shalini Saggu; Robert Lundy
Journal:  Brain Res       Date:  2009-08-21       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.